Journal of Obesity & Weight Loss Therapy
Open Access

Abstract

The glucagon-like peptide-1 receptor agonist (GLP-1RA) Semaglutide is the most recently approved agent of this drug class, and the only GLP-1RA currently available as both subcutaneous and oral formulation. While GLP-1RAs effectively improve glycemic control and cause weight loss, potential safety concerns have arisen over the years. For Semaglutide, such concerns have been addressed in the extensive phase 3 registration trials including cardiovascular outcome trials for both subcutaneous (SUSTAIN: Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) and oral (PIONEER: Peptide Innovation for the Early diabetes Treatment) Semaglutide and are being studied in further trials and registries, including real world data studies. In SUSTAIN programme, Semaglutide was associated with consistent reductions in HbA1c and higher proportions of subjects achieving glycaemic targets of <7.0% and ΓΆΒ?Β¤6.5%, vs comparators. In SUSTAIN 6, Semaglutide treated patients experienced a significant 26% risk reduction in the primary composite outcome. Given the beneficial metabolic and cardiovascular actions of Semaglutide, and the low risk for severe adverse events, Semaglutide has an overall favorable risk/benefit profile for patient with type 2 diabetes.

Biography

Hazem Rayyan is the Director of training program in Internal medicine in NWAFH. Previously, he worked as a consultant Endocrinologist in King Salman Military Hospital, Tabuk-KSA. Currently, he is working as a Endocrinologist in(JCDE) in Jordan Hospital. His main research